Welcome to our dedicated page for ResMed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on ResMed stock.
ResMed Inc. (NYSE: RMD, ASX: RMD) is a global leader in digital health and cloud-connected medical devices, focusing on innovative solutions that treat and prevent respiratory conditions like sleep apnea and COPD. By transforming patient care, ResMed empowers individuals to live healthier, higher-quality lives. Their diverse product portfolio includes flow generators, masks, and accessories designed to keep patients out of hospitals and manage chronic diseases effectively.
Operating in over 140 countries, ResMed’s cloud-connected medical devices provide data-driven insights used by patients, healthcare providers, and payers to deliver personalized and efficient healthcare. Their comprehensive out-of-hospital software platforms support professionals and caregivers, enhancing the quality of life and reducing healthcare costs. The company earns about two-thirds of its revenue from the Americas, with the remainder coming from Europe, Japan, and Australia.
In recent developments, ResMed successfully defended its intellectual property against a patent infringement claim by NYU, with the PTAB ruling in favor of ResMed on all challenged claims. This outcome underscores the company’s commitment to innovation, backed by over 9,500 issued or pending patents and designs.
ResMed also made headlines with a global field action to update guides for masks with magnets, ensuring user safety around medical implants. Their proactive approach and dedication to patient safety were evident as they addressed potential magnetic interference issues without necessitating a product recall.
Financially, ResMed continues to demonstrate strong growth. In the second quarter of fiscal year 2024, the company reported double-digit growth across its devices, masks, accessories, and residential care software businesses. This robust performance highlights ResMed’s strategic focus on expanding its product offerings and maintaining cost discipline.
ResMed's latest product launch, the AirCurve 11 series, further showcases their commitment to innovation. These bilevel PAP devices feature advanced digital technology to improve patient comfort and compliance, addressing challenges in CPAP therapy adaptation.
Continuing its leadership in respiratory care, ResMed actively participates in significant industry conferences such as the American Thoracic Society International Conference and SLEEP 2024, presenting crucial research on sleep disorders and their impact on health. This research supports the effectiveness of PAP therapy in reducing mortality and improving patient outcomes, solidifying ResMed’s role as a pioneer in the field.
With a clear focus on enhancing patient care through technology and innovation, ResMed is well-positioned to lead the expansion of sleep and respiratory health.
ResMed has acquired MEDIFOX DAN, a leading German software solutions provider, for €958.6 million ($997.5 million). This strategic acquisition marks ResMed's first expansion of its SaaS business into Germany, the second largest healthcare market globally. MEDIFOX DAN will enhance ResMed's portfolio with outpatient therapy service offerings, and its operations will integrate within ResMed's SaaS segment. The acquisition is expected to be accretive to non-GAAP diluted earnings per share, while ResMed plans to retain all MEDIFOX DAN employees and maintain its current brand.
ResMed (NYSE: RMD) reported a 5% year-over-year revenue growth for Q1 2023, totaling $950.3 million, with a 9% increase on a constant currency basis. Operating profit rose 5%, while non-GAAP operating profit increased 4%. Diluted earnings per share increased to $1.43, with a non-GAAP EPS of $1.51. The company noted strong sales in the Americas and expanding gross margins despite increased SG&A expenses. Additionally, ResMed announced the acquisition of mementor and unveiled plans to double its R&D workforce in Ireland.
ResMed (NYSE: RMD) will release its financial and operational results for Q1 FY 2023 on October 27, 2022, post-market hours. A webcast will follow to discuss these results and any additional forward-looking information. The earnings call will be accessible to international audiences, with a replay available shortly after. ResMed focuses on innovative healthcare solutions that enhance the quality of life for individuals with chronic diseases, aiming to lower costs for consumers and healthcare systems globally.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will participate in a fireside chat at the Bank of America Global Healthcare Conference on September 14, 2022, at 9:05 a.m. BST in London. This event will be accessible via a live webcast, with a replay available approximately three hours after the event until December 13, 2022. ResMed continues to innovate with digital health technologies and cloud-connected medical devices, aiming to enhance the quality of life for patients suffering from chronic diseases globally.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on September 12, 2022, at 8:45 a.m. ET in New York City. The event will include a live webcast, with a replay available three hours after it concludes, accessible until March 11, 2023. ResMed focuses on innovative solutions for chronic diseases, aiming to improve quality of life and reduce healthcare costs globally.
ResMed's latest research reveals that over 480 million people globally suffer from chronic obstructive pulmonary disease (COPD), a prevalence significantly higher—by 22–126%—than previous estimates. This figure could escalate to 592 million by 2050 if current trends in smoking and air pollution continue. COPD costs the EU approximately €48.4 billion annually, with the U.S. facing over $3 billion in hospitalization costs alone. The study urges immediate action for better screening and treatment, stressing the importance of reducing risk factors associated with COPD.
ResMed reported a 4% increase in year-over-year revenue for Q4 2022, totaling $914.7 million. Operating profit rose 6%, with diluted earnings per share at $1.33. Annual revenue reached $3.6 billion, marking a 12% growth. Despite a 90 bps contraction in gross margin to 56.6%, non-GAAP measures showed resilience with an operating profit increase of 8% for the year. The board declared a 5% increase in dividends to $0.44 per share. The company is optimistic about growth in FY23, aided by new product launches and an upcoming acquisition of MEDIFOX DAN for $1 billion.
ResMed has acquired Leipzig-based mementor as of August 1, 2022, enhancing its digital sleep medicine portfolio in Germany. This strategic move integrates mementor’s somnio, a digital insomnia therapy solution, into ResMed's offerings, filling a significant care gap for patients suffering from insomnia. Somnio, which is the only permanently approved Digital Health Application (DiGA) for insomnia in Germany, is now available via prescription and eligible for reimbursement. This acquisition aims to expand access to effective sleep treatments and leverage ResMed's network for greater adoption.
ResMed (NYSE: RMD) has announced it will release its fourth-quarter fiscal year 2022 financial results on August 11, 2022, after the NYSE closes. Following this, management will host a webcast to discuss the outcomes and other material information. The webcast will be accessible at http://investor.resmed.com. A replay will be available shortly post-webcast, including a phone replay accessible until August 25. ResMed continues to focus on innovative solutions for chronic disease management, aiming to improve quality of life and reduce healthcare costs.
ResMed has announced the promotion of Lucile Blaise to President of Sleep & Respiratory Care, effective July 1, 2022. Blaise, with over 25 years in the medtech industry, previously served as Vice President for Western Europe. She has been influential in establishing payer market access for digital health in France and Belgium and advocates for data privacy and real-world evidence in healthcare. CEO Mick Farrell praised her commitment to patient-centric care and innovative leadership, highlighting her vital role in improving treatments for chronic diseases.
FAQ
What is the current stock price of ResMed (RMD)?
What is the market cap of ResMed (RMD)?
What does ResMed Inc. specialize in?
Where does ResMed operate?
What are some of ResMed’s recent key developments?
How does ResMed ensure patient safety with its products?
What financial performance did ResMed report recently?
What innovations has ResMed introduced recently?
How does ResMed contribute to healthcare research?
What is ResMed’s approach to out-of-hospital care?
What kind of products does ResMed develop?
How does ResMed support its innovation?
